Precision Medicine Is Precisely Right Theme For Biopharma: Impact Of Therapy—Not Cost—Is Focus
This article was originally published in RPM Report
A Senate hearing on President Obama’s Precision Medicine initiative illustrates how well that theme plays for the biopharma sector. The focus was on the potential for highly effective targeted therapies to help patients—and even lower costs for the system. The price of the drugs themselves was not even raised.
You may also be interested in...
Despite her reputation as a populist, anti-corporate crusader, Elizabeth Warren did not focus on Big Pharma in her first years in the Senate. The headlines following a speech by Warren last week suggest that has changed – but the actual legislative proposal looks a lot different than the rhetoric makes it sound.
The questions posed by the FDA to its Oncologic Drugs Advisory Committee for its most recent meeting all but answer themselves. The committee ultimately supported the agency’s negative view of the applications under review, but pushback during the meeting may encourage the agency to strike a more neutral tone in the future.
The prototypical US FDA advisory committee review of a pending new drug application has become something of an endangered species. A suddenly busy October and November agenda suggests that might be changing.